In July 2026, Alligator discontinued independent development of mitazalimab and is seeking to out-license or divest the asset. The information below on mitazalimab and ATOR-4066 describes earlier development and is no longer updated.
Pipeline highlights:
- Tumor-directed immune activation via CD40
- Phase 3-ready lead candidate in pancreatic cancer
- Focused on high unmet medical need indications
- Platform built around mono- and bispecific antibody formats